MetaCap

AbCellera Biologics (ABCL) vs Enliven Therapeutics (ELVN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 176.1% versus a gain of 113.9%. Over five years, ELVN leads with a +254.6% price change compared with -30.7% for ABCL. Enliven Therapeutics is the larger company by market cap ($3.42 billion vs $3.16 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%ELVN+113.93%
+340%+146%-48%
Nov 21, 20251 yearNov 20, 2026
ABCL-38.67%ELVN+252.50%
+380%+135%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus ELVN key metrics
MetricABCLELVN
Share price$9.69$46.53
Market cap$3.16B$3.42B
1-day change-7.45%+0.26%
YTD return+183.33%+202.14%
1-year return+176.07%+113.93%
5-year return-30.74%+254.65%
EPS (TTM)$-0.48$-1.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M—
Revenue growth (YoY)+160.56%—
Net income (latest FY)$-146.41M$-103.69M
Operating margin-288.98%—
Net margin-194.88%—
52-week high$15.02$62.32
52-week low$2.75$14.79
Distance from 52-week high-35.46%-25.34%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+92.67%+59.75%
Average volume4.34M1.36M
Shares outstanding326.62M73.60M
Employees56265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed ELVN by 62.1 percentage points over the past year.

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About Enliven Therapeutics

ELVN stock →

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

ABCL vs ELVN FAQ

Which is bigger, AbCellera Biologics or Enliven Therapeutics?

Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.42B compared with $3.16B for AbCellera Biologics (ABCL).

Which stock has performed better over the past year, ABCL or ELVN?

ABCL returned +176.07% over the past 12 months, compared with +113.93% for ELVN (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and Enliven Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons